Will the new pharmaceutical lipid-aspirin complex formulation restore the once lost trust of aspirin on cardiovascular protection?

Over the years the goal of delivering therapeutic levels of aspirin (ASA) while reducing the risk of gastrointestinal (GI) injury has been the main goal. The novel concept of the pharmaceutical lipid-aspirin complex (PL-ASA) is supposed to produce more rapid and more extensive absorption in obese patients with type 2 diabetes.While initial data is certainly encouraging, it is important to keep in mind that none of pharmacokinetic and pharmacodynamic studies went beyond 7-days, thus the effects of chronic administration, which can alter the ASA pharmacodynamic response, remain unknown.In the meantime, television advertisements and other means are reaching audiences and encourage them to start using this product.Our Editorial raises questions and is trying to raise concerns to healthcare providers so their patients patiently wait for confirmation data that will eventually allow us to freely utilize this promising product in patients at risk of adverse cardiovascular events without concerns of ineffective protection.